A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

September 18, 2025

Study Completion Date

December 18, 2025

Conditions

Chronic Weight Management

Interventions

DRUG

ASC47 +Semaglutide

ASC47 single subcutaneous injection + Semaglutide QW for 4 weeks

DRUG

Placebo+Semaglutide

Placebo single subcutaneous injection + Semaglutide QW for 4 weeks

Trial Locations (1)

RECRUITING

Ascletis Clinical Site, San Antonio

All Listed Sponsors

lead

Ascletis Pharma (China) Co., Limited

INDUSTRY